Enterprise Value
-58.11M
Cash
257.7M
Avg Qtr Burn
-16.6M
Short % of Float
4.20%
Insider Ownership
20.23%
Institutional Own.
86.04%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Zetomipzomib (KZR-616) Details Chronic inflammatory disorder, Chronic kidney disease, Inflammatory disease, Kidney disease, Lupus nephritis | Phase 2b Initiation | |
KZR-616 Details Chronic inflammatory disorder, Inflammatory disease, Autoimmune disease | Phase 2 Update | |
Zetomipzomib (KZR-616) Details Autoimmune Hepatitis | Phase 2a Initiation | |
KZR-261 Details Solid tumor/s | Phase 1 Data readout |